Prostate Cancer Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Prostate Cancer stocks.

Prostate Cancer Stocks Recent News

Date Stock Title
May 1 EXEL Exelixis, Inc. (EXEL) Q1 2024 Earnings Call Transcript
Apr 30 EXEL Exelixis down 7% as Q1 financial results disappoint
Apr 30 EXEL Exelixis (EXEL) Reports Q1 Earnings: What Key Metrics Have to Say
Apr 30 EXEL Exelixis Inc (EXEL) Q1 2024 Earnings: Mixed Results Amidst Restructuring Efforts
Apr 30 JAZZ Jazz Pharmaceuticals Q1 2024 Earnings Preview
Apr 30 EXEL Exelixis Non-GAAP EPS of $0.17 misses by $0.12, revenue of $425.2M misses by $35.27M
Apr 30 EXEL Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update
Apr 30 MYGN Myriad Genetics to Release First Quarter 2024 Financial Results on May 7, 2024
Apr 30 LNTH Here's Why You Should Hold Lantheus (LNTH) in Your Portfolio Now
Apr 30 LNTH Lantheus Holdings (NASDAQ:LNTH) Knows How To Allocate Capital Effectively
Apr 30 AMGN Sandoz Settles Patent Dispute With Amgen Related To Bone Disorder Drug Denosumab
Apr 30 AMGN Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?
Apr 30 AMGN Sandoz, Amgen reach agreement resolving patent litigation over biosimilars
Apr 30 AMGN Sandoz reaches agreement with Amgen over patent dispute
Apr 29 EXEL Exelixis Q1 2024 Earnings Preview
Apr 29 AMGN AMGEN ANNOUNCES WEBCAST OF 2024 FIRST QUARTER FINANCIAL RESULTS
Apr 29 AMGN Amgen court hearing in patent lawsuit vs Sandoz over generic Prolia cancelled (update)
Apr 29 AMGN What's in the Cards for Amgen (AMGN) This Earnings Season?
Apr 29 AMGN Insights Into Amgen (AMGN) Q1: Wall Street Projections for Key Metrics
Apr 29 INO INOVIO to Participate in Upcoming Investor Conferences in May
Prostate Cancer

Prostate cancer is the development of cancer in the prostate, a gland in the male reproductive system. Most prostate cancers are slow growing; however, some grow relatively quickly. The cancer cells may spread from the prostate to other areas of the body, particularly the bones and lymph nodes. It may initially cause no symptoms. In later stages, it can lead to difficulty urinating, blood in the urine or pain in the pelvis, back, or when urinating. A disease known as benign prostatic hyperplasia may produce similar symptoms. Other late symptoms may include feeling tired due to low levels of red blood cells.Factors that increase the risk of prostate cancer include older age, a family history of the disease, and race. About 99% of cases occur in males over the age of 50. Having a first-degree relative with the disease increases the risk two to threefold. In the United States, it is more common in the African American population than the White American population. Other factors that may be involved include a diet high in processed meat, red meat or milk products or low in certain vegetables. An association with gonorrhea has been found, but a reason for this relationship has not been identified. An increased risk is associated with the BRCA mutations. Prostate cancer is diagnosed by biopsy. Medical imaging may then be done to determine if the cancer has spread to other parts of the body.Prostate cancer screening is controversial. Prostate-specific antigen (PSA) testing increases cancer detection, but it is controversial regarding whether it improves outcomes. Informed decision making is recommended when it comes to screening among those 55 to 69 years old. Testing, if carried out, is more reasonable in those with a longer life expectancy. While 5α-reductase inhibitors appear to decrease low-grade cancer risk, they do not affect high-grade cancer risk and thus are not recommended for prevention. Supplementation with vitamins or minerals does not appear to affect the risk.Many cases are managed with active surveillance or watchful waiting. Other treatments may include a combination of surgery, radiation therapy, hormone therapy or chemotherapy. When it only occurs inside the prostate, it may be curable. In those in whom the disease has spread to the bones, pain medications, bisphosphonates and targeted therapy, among others, may be useful. Outcomes depend on a person's age and other health problems as well as how aggressive and extensive the cancer is. Most men with prostate cancer do not end up dying from the disease. The 5-year survival rate in the United States is 99%. Globally, it is the second most common type of cancer and the fifth leading cause of cancer-related death in men. In 2012, it occurred in 1.1 million men and caused 307,000 deaths. It was the most common cancer in males in 84 countries, occurring more commonly in the developed world. Rates have been increasing in the developing world. Detection increased significantly in the 1980s and 1990s in many areas due to increased PSA testing. Studies of males who died from unrelated causes have found prostate cancer in 30% to 70% of those over age 60.

Browse All Tags